- Approval Id
- 2a3d7d660596b93f
- Drug Name
- ZINNAT TABLET 500 MG
- Product Name
- ZINNAT TABLET 500 MG
- Approval Number
- SIN02364P
- Approval Date
- 1988-11-03
- Registrant
- SANDOZ SINGAPORE PTE. LTD.
- Licence Holder
- SANDOZ SINGAPORE PTE. LTD.
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- TABLET, FILM COATED
- Dosage
- <p><strong>4.2 Posology and method of administration</strong><br>
The usual course of therapy is seven days (range five to ten days). The dose of <em>ZINNAT</em> that is selected to treat an individual infection should take into account:</p>
<ul>
<li>The expected pathogens and their likely susceptibility to <em>ZINNAT</em></li>
<li>The severity and the site of the infection</li>
<li>The age, weight and renal function of the patient: as shown below.</li>
</ul>
<p>The duration of therapy should be determined by the type of infection and the response of the patient, and should generally not be longer than recommended.</p>
<p><strong>Dosage in adults and children weighing more than 40 kg:</strong></p>
<img src="/TGIF/ZinnatTablet-Table1_020125.png" alt="Zinnat Tablet Dosage Table 1" /><br><br>
<p><strong>Dosage in children weighing between 20–40 kg:</strong></p>
<img src="/TGIF/ZinnatTablet-Table2_020125.png" alt="Zinnat Tablet Dosage Table 2" /><br><br>
<p><em>ZINNAT</em> tablets should not be crushed or split and are therefore unsuitable for treatment of patients, such as younger children, who cannot swallow whole tablets. Therefore, <em>ZINNAT</em> suspension is recommended for patients who cannot swallow whole tablets.<br>
When doses below 250 mg are required, <em>ZINNAT</em> FOR SUSPENSION 125mg/5ml should be used.</p>
<p>There is no experience of using <em>ZINNAT</em> in children under the age of 3 months.</p>
<p><strong>Dosage in renal impairment:</strong><br>
Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function, it is recommended that the dosage of cefuroxime be reduced to compensate for its slower excretion (see the table below).</p>
<img src="/TGIF/ZinnatTablet-Table3_020125.png" alt="Zinnat Tablet Dosage Table 3" /><br><br>
<p><strong>Method of administration:</strong><br>
Oral use.<br>
<em>ZINNAT</em> should be taken after food for optimum absorption.</p>
- Route Of Administration
- ORAL
- Indication Info
- <p><strong>4.1 Therapeutic indications</strong><br>
<em>ZINNAT</em> is an oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms.</p>
<p>It is indicated for the treatment of infections caused by susceptible bacteria. Susceptibility to <em>ZINNAT</em> will vary with geography and time, and it should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data (see <em>Section 5.1</em>, <em>Pharmacodynamics</em> – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
<p><strong>Indications include:</strong><br>
Upper respiratory tract infections (for example: ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis).</p>
<p>Lower respiratory tract infections (for example: pneumonia and acute exacerbations of chronic obstructive pulmonary disease).</p>
<p>Genito-urinary tract infections (for example: pyelonephritis, cystitis and urethritis).</p>
<p>Gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis.</p>
<p>Skin and soft tissue infections (for example: furunculosis, pyoderma and impetigo).</p>
- Contraindications
- <p><strong>4.3 Contraindications</strong><br>
Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>.</p>
- Atc Code
- J01DC02
- Atc Item Name
- cefuroxime
- Pharma Manufacturer Name
- SANDOZ SINGAPORE PTE. LTD.
